ORIONS Money Stocks

[DDHOUND]

PSTV 8-k Below. I do not see todays news released yet.

Other Events.

On August 17, 2022, Plus Therapeutics, Inc. (the “Company”) announced that it has been awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas to fund the continued development of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (“186RNL”), for the treatment of patients with leptomeningeal metastases (“LM”).

Previously, on August 13, 2022, the Company announced that the dose administered in the first cohort of the Company’s Phase 1/2a dose escalation trial of 186RNL for the treatment of patients with LM was well-tolerated with no treatment-related adverse events greater than grade 1, and that the three patients in the cohort experienced 186RNL distribution throughout the cerebrospinal fluid (“CSF”) subarachnoid space and a decreased CSF cell count after treatment, each of which was durable past one week.

Separately, on August 15, 2022, the Company announced that its Board of Directors has approved a share repurchase program pursuant to which the Company is authorized to repurchase up to $2.0 million of the Company’s outstanding common stock. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors, including consent of the Company’s lender. Repurchases may be made from time to time on the open market over the next 12 months. The Company is not obligated to acquire any shares and the program may be discontinued or suspended at any time.








https://www.sec.gov/ix?doc=/Archives/edgar/data/0001095981/000119312522223362/d373590d8k.htm